Nestle bids to take control of Seres’ C diff drug Vowst

pharmaphorum June 7, 2024
Phil Taylor

Swiss food giant Nestlé has said it wants to take full ownership of Seres Therapeutics’ Vowst microbiome therapy for Clostridiodes difficile infections (CDI), upgrading its current co-marketing interest.

So far, terms of the deal have not been disclosed, but Seres said it is expecting an infusion of capital, including an upfront payment, that will allow it to pay off all its debt and extend its cash runway into the fourth quarter of next year. The transaction is expected to be completed within the next 90 days.

Nestlé has a long-running collaboration with Seres that dates back to 2016, and in 2021 the company’s Health Science unit firmed up its commitment with a $175 million licensing fee and another $125 million...

Today's Sponsors

Today's Sponsor